<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948372</url>
  </required_header>
  <id_info>
    <org_study_id>2019ZDSYLL196-P01</org_study_id>
    <nct_id>NCT04948372</nct_id>
  </id_info>
  <brief_title>Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock</brief_title>
  <official_title>Effects of Terlipressin Added to Usual Care vs. Usual Care Alone on Renal Perfusion in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, randomized controlled trial aimed to investigate the effect of a fixed dose&#xD;
      of terlipressin added to usual care vs. usual care alone on renal perfusion in patients with&#xD;
      septic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Terlipressin is a synthetic vasopressin analog with great affinity to the V1 receptor&#xD;
      (vasoconstrictive effect), and could selectively contract efferent arterioles, increase&#xD;
      glomerular filtration pressure and renal perfusion. The investigators conducted this&#xD;
      open-label, randomized controlled trial to observe the effects of a fixed dose of&#xD;
      terlipressin added to usual care vs. usual care alone on renal perfusion in patients with&#xD;
      septic shock. Renal perfusion was monitored by renal contrast-enhanced ultrasound. The&#xD;
      primary outcome was peak intensity (renal perfusion parameter) at 24 hours after enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">June 28, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak intensity</measure>
    <time_frame>24 hours after enrollment</time_frame>
    <description>Peak intensity is the peak concentration of contrast agent, a kind of renal perfusion parameter monitored by renal contrast-enhanced ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>urine output, mL</measure>
    <time_frame>24 hours after enrollment</time_frame>
    <description>urine output with 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of acute kidney injury</measure>
    <time_frame>Within 28 days</time_frame>
    <description>Defined as serum creatinine increase≥50% within seven days or increase≥26.5 μmol/L within 48 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>The terlipressin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The usual care group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the usual care group were treated with standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin treatment</intervention_name>
    <description>Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.</description>
    <arm_group_label>The terlipressin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.</description>
    <arm_group_label>The usual care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult septic shock patients (age≥18 years old)&#xD;
&#xD;
          2. Norepinephrine dose was more than or equal to 15μg/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age older than 85 years&#xD;
&#xD;
          2. Serum creatinine more than 177 μmol/L&#xD;
&#xD;
          3. Acute myocardial ischemia&#xD;
&#xD;
          4. Acute mesenteric artery ischemia&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Expected death within 24 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Jingyuan,Xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>terlipressin</keyword>
  <keyword>renal perfusion</keyword>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

